Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity

Breast Cancer Research and Treatment

Volumn 154, Issue 3, 2015, Pages 609-616

  Chlebowski, R T ^a   Haque, R ^b   Hedlin, H ^c   Col, N ^d   Paskett, E ^e   Manson, J E ^f   Kubo, J T ^c   Johnson, K C ^g   Wactawski Wende, J ^h   Pan, K ⁱ   Anderson, G ^j  

^a LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

^b KAISER PERMANENTE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NEW ENGLAND   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^h UNIVERSITY AT BUFFALO   (United States)

ⁱ HARBOR UCLA MEDICAL CENTER   (United States)

^j Fred Hutchinson Cancer Research Center   (United States)

more..

Author keywords

Adjuvant breast cancer; Aromatase inhibitor; Benefit risk assessment; Endocrine therapy; Race ethnicity; Tamoxifen

Indexed keywords

AROMATASE INHIBITOR; PLACEBO; TAMOXIFEN; ANTINEOPLASTIC AGENT;

ADVERSE OUTCOME; AGE; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CEREBROVASCULAR ACCIDENT; DISTANT METASTASIS; ENDOMETRIUM CANCER; ETHNIC DIFFERENCE; HEART INFARCTION; HIP FRACTURE; HUMAN; HYSTERECTOMY; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; META ANALYSIS (TOPIC); POSTMENOPAUSE; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; ADJUVANT CHEMOTHERAPY; AGED; BREAST NEOPLASMS; ETHNOLOGY; FEMALE; META ANALYSIS; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTOR; TUMOR RECURRENCE;

AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; MYOCARDIAL INFARCTION; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS; TAMOXIFEN;

EID: 84948397844     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3647-1     Document Type: Article

References (31)

1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2015) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomized trials. Lancet 386:1341–1352
2. Braithwaite RS, Chlebowski RT, Lau J et al (2003) Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 18:937–947
3. Cuppone F, Bria E, Verma S et al (2008) Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trails. Cancer 112:260–267
4. Amir E, Seruga B, Niraula S et al (2011) Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systemic review and meta-analysis. J Natl Cancer Inst 103:1299–1309
5. Dowsett M, Cuzick J, Ingle J et al (2010) Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28:509–518
6. Chlebowski RT, Anderson GL, Geller M et al (2006) Coronary heart disease and stroke with aromatase inhibitor, tamoxifen, and menopausal hormone therapy use. Clin Breast Cancer Suppl 2:S58–S64
7. Ligibel JA, O’Malley JA, Fisher M et al (2012) Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients. Breast Cancer Res Treat 131(2):589–597
8. Chapman JAW, Meng D, Shepherd L et al (2008) Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst 100:252–260
9. Ring A, Sestak I, Baum M et al (2011) Influence of comorbidities and age on risk of death with recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination Trial. J Clin Oncol 29:4266–4427
10. Puhalla S, Jankowitz RC, Davidson NE (2011) Adjuvant endocrine therapy for breast cancer: don’t ditch the switch. J Natl Cancer Inst 103:1280–1281
11. Bardia A, Arieas ET, Zhang A et al (2012) Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. Breast Cancer Res Treat 131(3):907–914
12. Goss PE, Ingle JN, Ales-Martinez J et al (2011) Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364(25):2381–2391
13. Cuzick J, Sestak I, Forbes JF et al (2014) Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 383(9922):1041–1048
14. Freedman AN, Yu B, Gail MH et al (2011) Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol 29:2327–2333
15. Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333
16. Anderson GL, Limacher M, Assaf AR et al (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291(14):1701–1712
17. The Women’s Health Initiative Study Group (1998) Design of the Women’s Health Initiative clinical trial and observational study. Control Clin Trials 19(1):61–109
18. Anderson GL, Manson J, Wallace R et al (2003) Implementation of the Women’s Health Initiative study design. Ann Epidemiol 13(9 Suppl):S5–S17
19. Wasan KM, Goss PE, Pritchard PH et al (2012) Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: an NCIC CTG MA.17 sub-study. Breast Cancer Res Treat 136(3):769–776
20. Visvanathan K, Hurley P, Bantug E et al (2013) Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 31(23):2942–2962
21. Fisher B, Costantino JP, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90(18):1371–1388
22. Markopoulos C, Tzoracoleftherakis E, Polychronis A et al (2010) Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. Breast Cancer Res 12(2):R24
23. Coleman R, de Boer R, Eidtmann H et al (2013) Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol 24(2):398–405
24. Coleman RE, Rathbone E, Brown JE (2013) Management of cancer treatment-induced bone loss. Nat Rev Rheumatol 9(6):365–374
25. Vogel VG, Costantino JP, Wickerham DL et al (2002) Re: tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 94(19):1504
26. Chlebowski RT, Cuzick J, Amakye D et al (2009) Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer. Breast Suppl 2:S1–S11
27. Davies C, Pan H, Godwin J et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869):805–816
28. Gray RD, Rea DW, Handley K et al (2008) aTTom (adjuvant Tamoxifen—To offer more?): randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6934 women with estrogen receptor-positive (ER+) or ER untested breast cancer—preliminary results. J Clin Oncol 26(155):513
29. Goss PE, Ingle JN, Martino S et al (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97(17):1262–1271
30. Jakesz R, Greil R, Gnant M et al (2007) Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst 99(24):1845–1853
31. Mamounas EP, Jeong JH, Wickerham DL et al (2008) Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol 26(12):1965–1971